Using National Registries to Identify Targeted Therapies for Refractory Urticaria
Author:
Publisher
S. Karger AG
Subject
Immunology,General Medicine,Immunology and Allergy
Reference9 articles.
1. Türk M, Yılmaz İ. High-dose omalizumab versus ligelizumab for the treatment of chronic spontaneous urticaria: do not we need a head-to-head comparison? Int Arch Allergy Immunol. 2020 Dec;1-2:1–2.
2. Dekkers C, Alizadeh Aghdam M, de Graaf M, Knulst AC, Meijer Y, van den Reek JM, et al. Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients. Pediatr Allergy Immunol. 2020. DOI: 10.1111/pai.13426.
3. Maurer M, Costa C, Gimenez Arnau A, Guillet G, Labrador-Horrillo M, Lapeere H, et al. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study. Clin Exp Allergy. 2020 Oct;50(10):1166–75.
4. Maurer M, Giménez-Arnau AM, Sussman G, Metz M, Baker DR, Bauer A, et al. Ligelizumab for Chronic Spontaneous Urticaria. N Engl J Med. 2019 Oct;381(14):1321–32.
5. Edelman SM, Kukkonen AK, Mäkelä MJ. Eliciting allergens and treatment of anaphylaxis: report of the Finnish National Anaphylaxis Registry. Allergy. 2019 Oct;74(10):2010–3.
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Resistant Chronic Spontaneous Urticaria – A Case Series Narrative Review of Treatment Options;Allergy & Rhinology;2022-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3